# LN-144 (NCT02360579)

> Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02360579
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Iovance Biotherapeutics, Inc.
- Conditions: Metastatic Melanoma
- Interventions: Lifileucel
- Enrollment: 220
- Primary outcome: Disease Assessment for Objective Response Rate

## Indexed commentary on LN-144 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ln-144-nct02360579